TaiMed Biologics Inc. (TPEX:4147)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
88.40
-1.70 (-1.89%)
Apr 2, 2025, 11:00 AM CST

TaiMed Biologics Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Revenue
610.16491.78563.01413.44722.49
Upgrade
Revenue Growth (YoY)
24.07%-12.65%36.18%-42.77%2.55%
Upgrade
Cost of Revenue
398.94266.54347.3329.49311.77
Upgrade
Gross Profit
211.23225.23215.7183.96410.71
Upgrade
Selling, General & Admin
75.2997.1974.45109.7259.55
Upgrade
Research & Development
388.21294.28333.12460.6394.45
Upgrade
Other Operating Expenses
----89.47
Upgrade
Operating Expenses
463.49391.46407.57570.32543.47
Upgrade
Operating Income
-252.27-166.23-191.86-486.37-132.76
Upgrade
Interest Expense
-12.6-14.81-10.1-7.44-4.09
Upgrade
Interest & Investment Income
33.978.464.344.038.48
Upgrade
Currency Exchange Gain (Loss)
26.352.0448.69-11.382.47
Upgrade
Other Non Operating Income (Expenses)
5.054.782.443.454.35
Upgrade
EBT Excluding Unusual Items
-199.51-165.76-146.48-497.7-121.55
Upgrade
Gain (Loss) on Sale of Investments
--29.05-122.8126.76-63.13
Upgrade
Gain (Loss) on Sale of Assets
-2.32--0.011.37
Upgrade
Pretax Income
-201.83-194.81-269.29-470.93-183.3
Upgrade
Net Income
-201.83-194.81-269.29-470.93-183.3
Upgrade
Net Income to Common
-201.83-194.81-269.29-470.93-183.3
Upgrade
Shares Outstanding (Basic)
268253252252252
Upgrade
Shares Outstanding (Diluted)
268253252252252
Upgrade
Shares Change (YoY)
6.08%0.18%0.04%0.03%0.07%
Upgrade
EPS (Basic)
-0.75-0.77-1.07-1.87-0.73
Upgrade
EPS (Diluted)
-0.75-0.77-1.07-1.87-0.73
Upgrade
Free Cash Flow
-387.61-31.75-608.77-220.96-255.55
Upgrade
Free Cash Flow Per Share
-1.45-0.13-2.41-0.88-1.01
Upgrade
Gross Margin
34.62%45.80%38.31%20.31%56.85%
Upgrade
Operating Margin
-41.34%-33.80%-34.08%-117.64%-18.38%
Upgrade
Profit Margin
-33.08%-39.61%-47.83%-113.90%-25.37%
Upgrade
Free Cash Flow Margin
-63.52%-6.46%-108.13%-53.44%-35.37%
Upgrade
EBITDA
-104.49-17.72-42.22-336.32.3
Upgrade
EBITDA Margin
-17.13%-3.60%-7.50%-81.34%0.32%
Upgrade
D&A For EBITDA
147.78148.51149.64150.07135.06
Upgrade
EBIT
-252.27-166.23-191.86-486.37-132.76
Upgrade
EBIT Margin
-41.34%-33.80%-34.08%-117.64%-18.38%
Upgrade
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.